Solutions
About Us
Insights
Careers
Contact us
Contact Us
Customer Support
Customer Support

Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis. Avila RL, Croteau NS, Tang F, Simeone JC, Jomaa K, Bian B, Gianinazzi M. Ther Adv Neurol Disord. 2025

Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Azimpour K, Dorling P, Koulinska I, Kunduri S, Lan Z, Poritz J, Tremblay G, Raad-Faherty A. Adv Ther. 2025

Mucosal and Transmural Healing and Long-term Outcomes in Crohn’s Disease. Sands BE, Danese S, Chapman JC, Gurjar K, Grieve S, Thakur D, Griffith J, Joshi N, Kligys K, Dignass A. Inflamm Bowel Dis. 2025

Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments. van Beekhuizen S, Che M, Monfort L, Hashim M, Azough A, Kubitz N, Griffin A, Price M. Pharmacoecon Open. 2025

PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis. Huerta JL, Ta A, Vinand E, Torres GI, Wannaadisai W, Huang L. Hum Vaccin Immunother. 2025

A group concept mapping study of stakeholder perspectives on digital therapeutics economic value drivers. Sapanel Y, Cloutier LM, Tremblay G, Bourcet A, Koerber F, Lariviere D, Tadeo X, Ho D. NPJ Digit Med. 2025

Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study. Merseburger AS, Dornstauder E, Ohlmann CH, Aprikian A, Junker S, Hahn P, Chilelli A, Stoelzel M, Serikoff A, Spitzer SG. Adv Ther. 2025

Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. J Comp Eff Res. 2025

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, Schepart A, Hughes DM, Hart J, Hlavacek P. Clinicoecon Outcomes Res. 2025

Webinar – Navigating the First Year of EU JCA Implementation: Updates, Methodological Insights, and Bridging Local HTA Realities